ChromaGenix

Summary

• Newly formed company ChromaGenix builds on the platform and scientific team of LigaTrap Technologies, LLC, originally spun out of NC State
• The company will focus on the scale and commercialization of ligands, resins, and membrane products for advanced biotherapeutics
• Will create up to 40 jobs, including in-house and field-based customer application support teams
• A newly constructed 6,500 sq. ft. GMP and R&D facility will support in-house development and manufacturing
• All LigaTrap staff have transitioned to ChromaGenix, ensuring full continuity for customers

ChromaGenix: A New Chapter for Proven Technology

ChromaGenix is a new company formed by BioProcess360 Partners to build on the strong technical foundation of LigaTrap Technologies, LLC. The formation follows the full transfer of LigaTrap’s IP, core technologies, and team, ensuring continuity for customers while accelerating the development and commercialization of purification solutions for gene therapies, vaccines, and other advanced biotherapeutics.

ChromaGenix will scale the peptide-based ligand discovery platform pioneered at NC State and proven through global research and industry collaborations, with an expanded focus on delivering high-performance resins, ligands, and membrane solutions for challenging downstream bioprocessing.

“We have always believed our technology had the potential to compete with much larger players in the biotech space, and our participation in international consortia and growing client base gave us confidence in the strength of what we were building,” said Dr. Michael Crapanzano, Co-Founder of LigaTrap. “From our first interactions with BioProcess360 Partners, it was clear to me that their experience in scale-up and commercialization of affinity resins in the bioprocessing space is valuable. Pairing this with the ligand discovery expertise of Dr. Stefano Menegatti (Professor at NC State and Chief Technology Officer at ChromaGenix) we’re on a solid path for success as we build out a market leading innovation. The ‘Think and Do’ mindset from NC State shaped us early on — and that same spirit now lives on in ChromaGenix.”

Continuity, Scale, and Vision

ChromaGenix will receive up to $35 million in investment over five years, funding a new 6,500 sq. ft. R&D and GMP facility, expanded customer support, and up to 40 new roles in scientific, commercial, and operational areas. All former LigaTrap employees have transitioned to ChromaGenix, ensuring uninterrupted support and expertise for existing customers.

“This is the beginning of a new venture that we believe will reshape how the industry approaches purification for modern medicines,” said Chris Major, Founding Partner at BioProcess360 Partners. “ChromaGenix represents a rare convergence of breakthrough science, practical experience, and long-term investment — all focused on helping manufacturers unlock the full potential of advanced therapeutics.”

“From day one, it was clear the team at LigaTrap had built something special — not just in terms of technology, but in culture and commitment to solving real challenges,” said Brad Beatty, Founding Partner at BioProcess360 Partners. “We’re honored to carry that work forward, and we’ve invested with purpose to scale the vision they’ve developed. ChromaGenix is not just a business opportunity — it’s a meaningful continuation of a mission we deeply believe in.”

What’s Next?

Customers and partners can rest assured that there is no disruption in continuity. All products, support channels, and commercial relationships will continue without interruption.

• All LigaTrap staff have transitioned to ChromaGenix, and your existing contacts remain the same
• Product availability and technical support will continue as usual — with no changes to ordering or delivery
• Over the coming months, the ChromaGenix brand will gradually roll out across product packaging, communications, and documentation
• Until then, you can continue to access support via ligatrap.com, existing email addresses, and phone numbers

We’re the same team, with the same science — and even greater resources to support your next breakthrough.